2013
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research 2013, 73: 6516-6525. PMID: 24014597, PMCID: PMC6135947, DOI: 10.1158/0008-5472.can-13-0967.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAxl Receptor Tyrosine KinaseBlotting, WesternCell AdhesionCell CycleCell MovementCell ProliferationDisease ProgressionFemaleFluorescent Antibody TechniqueHumansImmunoprecipitationInflammatory Breast NeoplasmsMediator ComplexMiceNeoplasm InvasivenessProto-Oncogene ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, Small InterferingSignal TransductionTumor Cells, CulturedConceptsInflammatory breast cancerBreast cancerAxl expressionMalignant propertiesHigh tumoral expressionIBC cell proliferationMatrix metalloproteinase-9Inhibited tumor growthIBC specimensIBC cellsShorter survivalTumoral expressionProteasome-dependent degradationMetalloproteinase-9TIG1 expressionNF-κBTherapeutic targetTumor growthReceptor tyrosine kinasesAxl functionLethal formAxlIBC treatmentCancerAggressive properties
2010
Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer
Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research 2010, 70: 8852-8862. PMID: 20959472, DOI: 10.1158/0008-5472.can-10-1039.Peer-Reviewed Original ResearchConceptsPathologic complete responseBreast cancerClinical subtypesPredictive valueHigher pathologic complete responseHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Different clinical subsetsDistinct prognostic informationNode-negative patientsGrowth factor receptor 2Different clinical subtypesBreast cancer cell linesFactor receptor 2Subtype-specific inhibitionCancer cell linesNeoadjuvant chemotherapyAdjuvant therapyComplete responseClinical subsetsWorse prognosisPrognostic valuePrognostic informationClinical subgroupsExpression patterns
2005
Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo
Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo. Cell Cycle 2005, 4: 1149-1152. PMID: 16103753, DOI: 10.4161/cc.4.9.2038.Peer-Reviewed Original ResearchMeSH KeywordsAlternative SplicingBreast NeoplasmsCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Expression RegulationHumansImmunohistochemistryIn Vitro TechniquesInhibitory Concentration 50Microtubule-Associated ProteinsMicrotubulesModels, BiologicalOligonucleotide Array Sequence AnalysisPaclitaxelRNA, MessengerRNA, Small InterferingTau ProteinsTubulinConceptsPaclitaxel sensitivityHuman breast cancer tissuesBreast cancer tissuesHuman breast cancerRole of tauCell linesRegulation of tauBreast cancerCancer tissuesProtein tauNovel markerLow expressionMicrotubule associated proteinNovel mediatorPaclitaxelTauPhysiological levelsGene expression analysisRecent findingsMediatorsMarkersAssociated proteinsChemotherapyCancerExpression analysis